Biostar Pharmaceuticals, Inc. to Present at the Brean Murray, Carret & Co. China Growth Conference
XIANYANG, China, Nov. 4 /PRNewswire-Asia-FirstCall/ -- Biostar
Pharmaceuticals, Inc. (OTC Bulletin Board: BSPM) ("Biostar" or "the Company"),
a Xianyang-based developer, manufacturer and supplier of pharmaceutical
products and medical nutrients addressing a variety of diseases and conditions,
today announced that it will present at the Brean Murray, Carret & Co. China
Growth Conference, to be held November 19-20, 2009, at the Millennium Broadway
Hotel, 150 West 45th Street, New York City.
Mr. Ronghua Wang, Chief Executive Officer and Ms. Elaine Zhao, Chief
Financial Officer, are scheduled to present at 11:20 am ET on Thursday
November 19 and are available to host one-on-one meetings with conference
attendees throughout the one-day event. Mr. Wang and Ms. Zhao will discuss the
Company's products including Biostar's leading hepatitis B medicine, Xin
Aoxing, the Company's expansion into rural networks in China, financial
results, and the Company's long-term growth strategies.
Registration is mandatory. For more information on the conference, contact
your Brean Murray, Carret & Co. representative. To register please visit or
contact Lindsay Zuckerman at 212-702-6577 or via email at
Lindsay.Zuckerman@bmur.com.
About Biostar Pharmaceuticals, Inc.
Biostar Pharmaceuticals, Inc., through its wholly-owned subsidiary in
China, develops, manufactures and markets pharmaceutical and medical nutrient
products for a variety of diseases and conditions. The Company's most popular
product is its Xin Ao Xing Oleanolic Acid Capsule, an over-the-counter ("OTC")
medicine for chronic hepatitis B, a disease affecting approximately 10% of the
Chinese population. In addition to its hepatitis product, Biostar manufactures
two broad-based OTC products, two prescription-based pharmaceuticals and ten
nutrients. The Company has adopted international standards and is in the
process of applying for two patents.
Safe Harbor
Certain statements in this release concerning our future growth prospects
are forward-looking statements, within the meaning of Section 27A of the U.S.
Securities Act of 1933, as amended, and Section 21E of the U.S. Securities
Exchange Act of 1934, as amended, which involve a number of risks and
uncertainties that could cause actual results to differ materially from those
in such forward-looking statements. The risks and uncertainties relating to
these statements include, but are not limited to, risks and uncertainties
regarding the success of our investments, risks and uncertainties regarding
fluctuations in earnings, our ability to sustain our previous levels of
profitability including on account of our ability to manage growth, intense
competition, wage increases in China, our ability to attract and retain highly
skilled professionals, time and cost overruns on fixed-price, fixed-time frame
contracts, client concentration, our ability to successfully complete and
integrate potential acquisitions, withdrawal of governmental fiscal incentives,
political instability and regional conflicts and legal restrictions on raising
capital or acquiring companies outside China. Additional risks that could
affect our future operating results are more fully described in our United
States Securities and Exchange Commission filings including our S-1 dated June
27, 2008, our Quarterly Report on Form 10-Q for the quarter ended June 30,
2009, our 10-K for the year ended December 31, 2008, and other recent filings.
These filings are available at http://www.sec.gov. We may, from time to time,
make additional written and oral forward-looking statements, including
statements contained in our filings with the Securities and Exchange
Commission and our reports to shareholders. We do not undertake to update any
forward-looking statements that may be made from time to time by or on our
behalf.
